Faradina Qorina Nadzif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Faradina Qorina Nadzif has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Heny Ekowati
Department of Pharmacy, Faculty of Health Sciences, Jenderal Soedirman University, Purwokerto, Indonesia
2 shared publications - Masita Wulandari Suryoputri
Laboratory of Pharmacology and Clinical Pharmacy, Faculty of Health Sciences, Universitas Jenderal Soedirman, Purwokerto
2 shared publications - Hanif Nasiatul Baroroh
Department of Pharmacy, Faculty of Health Sciences, Universitas Jenderal Soedirman. Purwokerto (Indonesia)
1 shared publication - Nialiana Endah Endriastuti
Department of Pharmacy, Faculty of Health Sciences, Universitas Jenderal Soedirman. Purwokerto (Indonesia)
1 shared publication
Latest Publications
- Open Access
- 4 February 2023
- Published by Universitas Jenderal Soedirman in Acta Pharmaciae Indonesia : Acta Pharm Indo
- Vol. 11 (1) , 7548
The effectiveness of N-acetylcysteine in alleviating clinical Symptoms of COVID-19 hospitalized patients at Santa Elisabeth Purwokerto General Hospital, Indonesia
Background: COVID-19 has been associated with increased innate immune system activation, leading to increased mucus production, inflammation, and tissue damage. N-Acetylcystysteine (NAC), an antioxidant and mucolytic, has demonstrated potential as a COVID-19 therapy. Objective: The purpose of this study was to evaluate the effectiveness of NAC on the clinical symptoms of hospitalized COVID-19 patients at Santa Elisabeth Purwokerto General Hospital in Indonesia. Methods: An observational analytical study design was employed, with data collected from the medical records of hospitalized COVID-19 patients at Santa Elisabeth Purwokerto General Hospital over the period of July 2020 to July 2021. The study included 209 patients who met the eligibility criteria. Results: The results indicated that the use of NAC affected the clinical symptoms of cough, oxygen saturation (SPO2), and respiratory rate in patients with mild and moderate degrees of COVID-19 patients (p0.05). Conclusion: This study suggests that NAC may be a useful treatment option for patients with mild and moderate COVID-19. Further research is needed to confirm these findings and determine their effectiveness in severe cases.
- 4 February 2023
- Published by Universitas Jenderal Soedirman in Acta Pharmaciae Indonesia : Acta Pharm Indo
- Vol. 11 (1) , 7548
Open AccessThe effectiveness of N-acetylcysteine in alleviating clinical Symptoms of COVID-19 hospitalized patients at Santa Elisabeth Purwokerto General Hospital, Indonesia
Background: COVID-19 has been associated with increased innate immune system activation, leading to increased mucus production, inflammation, and tissue damage. N-Acetylcystysteine (NAC), an antioxidant and mucolytic, has demonstrated potential as a COVID-19 therapy. Objective: The purpose of this study was to evaluate the effectiveness of NAC on the clinical symptoms of hospitalized COVID-19 patients at Santa Elisabeth Purwokerto General Hospital in Indonesia. Methods: An observational analytical study design was employed, with data collected from the medical records of hospitalized COVID-19 patients at Santa Elisabeth Purwokerto General Hospital over the period of July 2020 to July 2021. The study included 209 patients who met the eligibility criteria. Results: The results indicated that the use of NAC affected the clinical symptoms of cough, oxygen saturation (SPO2), and respiratory rate in patients with mild and moderate degrees of COVID-19 patients (p0.05). Conclusion: This study suggests that NAC may be a useful treatment option for patients with mild and moderate COVID-19. Further research is needed to confirm these findings and determine their effectiveness in severe cases.
- Open Access
- 31 March 2022
- Published by Universitas Jenderal Soedirman in Acta Pharmaciae Indonesia : Acta Pharm Indo
- Vol. 10 (1) , 5776
Drug utilization of N-Acetylcysteine in COVID-19 inpatients at Santa Elisabeth Hospital, Purwokerto
Background: COVID-19 is associated to an oxidant-antioxidant imbalance, which leads to inflammation and tissue damage. N-Acetylcysteine (NAC), in addition to being a mucolytic, has been shown to be an effective antioxidant in the therapy of COVID-19. Objective: The purpose of this study is to evaluate at the NAC usage profile in COVID-19 inpatients at Santa Elisabeth Hospital in Purwokerto. Methods: A descriptive observational design was used to perform the study. Retrospective data were obtained from medical records from July 2020 to July 2021. All patients who met the inclusion criteria were sampled using the total sampling technique. Results: NAC was commonly administered to COVID-19 inpatients who have a mild illness of the disease. The most common symptoms were cough and fever. Patients with mild and moderate severity were given NAC orally (600 mg 3 times a day) and intravenously (5 gram/day), respectively. The duration of NAC administration was in the range of 8-14 days. Conclusion: NAC was one of the therapies used at Santa Elisabeth Hospital Purwokerto for COVID-19 inpatients.
- 31 March 2022
- Published by Universitas Jenderal Soedirman in Acta Pharmaciae Indonesia : Acta Pharm Indo
- Vol. 10 (1) , 5776
Open AccessDrug utilization of N-Acetylcysteine in COVID-19 inpatients at Santa Elisabeth Hospital, Purwokerto
Background: COVID-19 is associated to an oxidant-antioxidant imbalance, which leads to inflammation and tissue damage. N-Acetylcysteine (NAC), in addition to being a mucolytic, has been shown to be an effective antioxidant in the therapy of COVID-19. Objective: The purpose of this study is to evaluate at the NAC usage profile in COVID-19 inpatients at Santa Elisabeth Hospital in Purwokerto. Methods: A descriptive observational design was used to perform the study. Retrospective data were obtained from medical records from July 2020 to July 2021. All patients who met the inclusion criteria were sampled using the total sampling technique. Results: NAC was commonly administered to COVID-19 inpatients who have a mild illness of the disease. The most common symptoms were cough and fever. Patients with mild and moderate severity were given NAC orally (600 mg 3 times a day) and intravenously (5 gram/day), respectively. The duration of NAC administration was in the range of 8-14 days. Conclusion: NAC was one of the therapies used at Santa Elisabeth Hospital Purwokerto for COVID-19 inpatients.